• Home
  • Search Results

Research Studies

UNC-Chapel Hill Lineberger Comprehensive Cancer Center

268 studies match your search

Adults with Blood Cancer

To find out if the study drug AZD9829 is safe and tolerable and effective in treating blood cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Open

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin s Lymphoma

Do you have a type of cancer known as Relapsed Hodgkin's Lymphoma?Has your cancer come back, or not get better with the last treatment you received ? If so, you may be able to participate in a gene therapy study to see if we can use your body's own immune cells as a treatment for your HL. (Example: Do you know your blood pressure? Do you sit too much at work? If you have a desk job and higher than normal blood pressure (but are not taking blood pressure medication), you may be able to participate in a research study to find out if sitting less during the workday can lower

Age & Gender
  • 3 years ~ 17 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)

Optimizing Nutrition and Exercise in Childhood Acute Lymphoblastic Leukemia

In this study, we want to determine if dietary intervention is feasible for patients being treated for leukemia or lymphoma.

Age & Gender
  • 8 years ~ 21 years
  • Male, Female
Study Interest
  • Cancer (Leukemia, Lymphoma)

Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients With Soft Tissue Sarcoma

In this study, we want to find out if a combination of 3 different study drugs (Cabozantinib, Ipilimumab, and Nivolumab) will affect the progression of Soft Tissue Sarcoma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Sarcoma (bone and soft tissue))

Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer

You are asked to participate in this research study of a new immunotherapy combination with chemotherapy in metastatic triple negative breast cancer. Immunotherapy is a form of cancer therapy that activates a patient's immune system to fight the cancer in a patient's body. Unfortunately, only a limited number of patients with metastatic triple negative breast cancer currently respond to FDA approved forms of immunotherapy. CDX-301 and CDX-1140 are two new immunotherapy drugs that are thought to kickstart the immune response against cancers even in patients who do not have an adequate immune response against their cancer to start with. Some studies suggest that combining these drugs with chemotherapy can most effectively kickstart this immune response and lead to improved clinical outcomes.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Phase 2 Relapsed or Refractory Multiple Myeloma Study

Have you been diagnosed with relapsed or refractory multiple myeloma? If so you may be able to take part in a research study looking at the safety and efficacy of giving BMS-986393 to patients with multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)

ONC-392 plus Lu 177 vipivotide in ARTA resistant mCRPC

The main purpose of the study is to determine whether the study drug, ONC-392, together with a standard of care drug PLUVICTO® (Lutetium Lu 177 Vipivotide Tetraxetan), are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with the standard of care PLUVICTO® alone.

Age & Gender
  • 18 years ~ 99 years
  • Male
Study Interest
  • Cancer (Prostate)
  • Men's Health
Open

Cancer Family History in Black Families

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
  • Healthy Volunteer or General Population
  • Minority Health
Visit Location
100% Remote (online, phone, text)
Open

SPECT-CT Guided Elective Contralateral Neck Treatment for Pts With Lateralized Oropharyngeal Cancer

Have you been diagnosed with Lateralized Oropharyngeal Cancer . If so, you may be able to take part in a research study looking at the safety by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT) compared to the usual treatment when radiotherapy is given .

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Head and Neck)

A Comparator Study of a Tasso device to traditional venous blood sampling methods for CBC in patients with leukemia, lymphoma, or other blood cell disorders

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Leukemia, Lymphoma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research